Supplemental Table 4. Key Biomarkers for KRAS mutation subtypes in adenocarcinoma (A) and squamous cell (B) NSCLC histologies.
No takes yet. Share an insight, caveat, or question.
Judd et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: